Background Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. Results Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. Conclusions Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-09097-5.
【저자키워드】 COVID-19, SARS-CoV-2, mRNA vaccination, antibody, Multiple myeloma, 【초록키워드】 mRNA vaccination, Vaccine, vaccination, immunogenicity, therapy, mRNA vaccine, Vaccine hesitancy, mRNA vaccines, Adverse reactions, Seroconversion, Multiple myeloma, RBD, Patient, trials, dose, Adverse reaction, leads, supplementary material, binding domain, reassurance, Result, Rate, detectable, characterized, seroconverted, receive, reactogenic, were excluded, 【제목키워드】 vaccination, Safety, Antibody Response, Patient, Messenger RNA,